Literature DB >> 11827798

The role of antibodies to Plasmodium falciparum-infected-erythrocyte surface antigens in naturally acquired immunity to malaria.

Peter C Bull, Kevin Marsh.   

Abstract

Plasmodium falciparum, the most virulent species of human malaria parasite, causes 1-3 million deaths per year. Because this parasite is susceptible to naturally acquired host immunity the main burden of diseases falls on young children. The mechanism of this immunity is still unclear. However, the parasite makes a considerable investment in the insertion of highly polymorphic antigens (parasite-infected-erythrocyte surface antigens, PIESA) on the infected erythrocyte surface, and these antigens are potentially important immune targets.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827798     DOI: 10.1016/s0966-842x(01)02278-8

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  68 in total

1.  Small variant STEVOR antigen is uniquely located within Maurer's clefts in Plasmodium falciparum-infected red blood cells.

Authors:  M Kaviratne; S M Khan; W Jarra; P R Preiser
Journal:  Eukaryot Cell       Date:  2002-12

Review 2.  Understanding naturally acquired immunity to Plasmodium falciparum malaria.

Authors:  D J Roberts
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

3.  Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adults.

Authors:  Obinna N Nnedu; Michael P O'Leary; Daniel Mutua; Beth Mutai; Mina Kalantari-Dehaghi; Al Jasinskas; Rie Nakajima-Sasaki; Grace John-Stewart; Phelgona Otieno; Xiaowu Liang; John Waitumbi; Francis Kimani; David Camerini; Philip L Felgner; Judd L Walson; Adam Vigil
Journal:  Proteomics Clin Appl       Date:  2011-12       Impact factor: 3.494

4.  Antibody reactivity to linear epitopes of Plasmodium falciparum cytoadherence-linked asexual gene 9 in asymptomatic children and adults from papua new Guinea.

Authors:  Katharine R Trenholme; Craig S Boutlis; Rachel Kuns; Moses Lagog; Moses J Bockarie; Michelle L Gatton; David J Kemp; Michael F Good; Nicholas M Anstey; Donald L Gardiner
Journal:  Am J Trop Med Hyg       Date:  2005-06       Impact factor: 2.345

5.  Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria.

Authors:  Faith H A Osier; Gregory Fegan; Spencer D Polley; Linda Murungi; Federica Verra; Kevin K A Tetteh; Brett Lowe; Tabitha Mwangi; Peter C Bull; Alan W Thomas; David R Cavanagh; Jana S McBride; David E Lanar; Margaret J Mackinnon; David J Conway; Kevin Marsh
Journal:  Infect Immun       Date:  2008-03-03       Impact factor: 3.441

6.  Why does immunity to parasites take so long to develop?

Authors:  Maria Yazdanbakhsh; David L Sacks
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

Review 7.  The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology.

Authors:  K Artavanis-Tsakonas; J E Tongren; E M Riley
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

8.  The immunization-induced antibody response to the Anaplasma marginale major surface protein 2 and its association with protective immunity.

Authors:  Susan M Noh; Yan Zhuang; James E Futse; Wendy C Brown; Kelly A Brayton; Guy H Palmer
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

9.  Pretreatment with Cry1Ac protoxin modulates the immune response, and increases the survival of Plasmodium-infected CBA/Ca mice.

Authors:  Martha Legorreta-Herrera; Rodrigo Oviedo Meza; Leticia Moreno-Fierros
Journal:  J Biomed Biotechnol       Date:  2010-03-11

10.  Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.

Authors:  Enmoore Lin; Benson Kiniboro; Laurie Gray; Stuart Dobbie; Leanne Robinson; Annemarie Laumaea; Sonja Schöpflin; Danielle Stanisic; Inoni Betuela; Melinda Blood-Zikursh; Peter Siba; Ingrid Felger; Louis Schofield; Peter Zimmerman; Ivo Mueller
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.